1
|
Velazquez FN, Stith JL, Zhang L, Allam AM, Haley J, Obeid LM, Snider AJ, Hannun YA. Targeting sphingosine kinase 1 in p53KO thymic lymphoma. FASEB J 2023; 37:e23247. [PMID: 37800872 DOI: 10.1096/fj.202301417r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Revised: 09/19/2023] [Accepted: 09/26/2023] [Indexed: 10/07/2023]
Abstract
Sphingosine kinase 1 (SK1) is a key sphingolipid enzyme that is upregulated in several types of cancer, including lymphoma which is a heterogenous group of malignancies. Treatment for lymphoma has improved significantly by the introduction of new therapies; however, subtypes with tumor protein P53 (p53) mutations or deletion have poor prognosis, making it critical to explore new therapeutic strategies in this context. SK1 has been proposed as a therapeutic target in different types of cancer; however, the effect of targeting SK1 in cancers with p53 deletion has not been evaluated yet. Previous work from our group suggests that loss of SK1 is a key event in mediating the tumor suppressive effect of p53. Employing both genetic and pharmacological approaches to inhibit SK1 function in Trp53KO mice, we show that targeting SK1 decreases tumor growth of established p53KO thymic lymphoma. Inducible deletion of Sphk1 or its pharmacological inhibition drive increased cell death in tumors which is accompanied by selective accumulation of sphingosine levels. These results demonstrate the relevance of SK1 in the growth and maintenance of lymphoma in the absence of p53 function, positioning this enzyme as a potential therapeutic target for the treatment of tumors that lack functional p53.
Collapse
Affiliation(s)
- Fabiola N Velazquez
- Department of Medicine, Stony Brook University, Stony Brook, New York, USA
- Cancer Center, Stony Brook University, Stony Brook, New York, USA
| | - Jeffrey L Stith
- Department of Medicine, Stony Brook University, Stony Brook, New York, USA
- Cancer Center, Stony Brook University, Stony Brook, New York, USA
| | - Leiqing Zhang
- Department of Medicine, Stony Brook University, Stony Brook, New York, USA
- Cancer Center, Stony Brook University, Stony Brook, New York, USA
| | - Amira M Allam
- Department of Medicine, Stony Brook University, Stony Brook, New York, USA
- Cancer Center, Stony Brook University, Stony Brook, New York, USA
| | - John Haley
- Biological Mass Spectrometry Center, Stony Brook Medicine, Stony Brook University, Stony Brook, New York, USA
| | - Lina M Obeid
- Department of Medicine, Stony Brook University, Stony Brook, New York, USA
- Cancer Center, Stony Brook University, Stony Brook, New York, USA
| | - Ashley J Snider
- Department of Medicine, Stony Brook University, Stony Brook, New York, USA
- Cancer Center, Stony Brook University, Stony Brook, New York, USA
- School of Nutritional Sciences and Wellness, College of Agriculture and Life Sciences, and University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA
| | - Yusuf A Hannun
- Department of Medicine, Stony Brook University, Stony Brook, New York, USA
- Cancer Center, Stony Brook University, Stony Brook, New York, USA
| |
Collapse
|
2
|
Velazquez FN, Viscardi V, Montemage J, Zhang L, Trocchia C, Delamont MM, Ahmad R, Hannun YA, Obeid LM, Snider AJ. A Milk-Fat Based Diet Increases Metastasis in the MMTV-PyMT Mouse Model of Breast Cancer. Nutrients 2021; 13:nu13072431. [PMID: 34371939 PMCID: PMC8308868 DOI: 10.3390/nu13072431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/01/2021] [Accepted: 07/12/2021] [Indexed: 11/30/2022] Open
Abstract
A high-fat diet (HFD) and obesity are risk factors for many diseases including breast cancer. This is particularly important with close to 40% of the current adult population being overweight or obese. Previous studies have implicated that Mediterranean diets (MDs) partially protect against breast cancer. However, to date, the links between diet and breast cancer progression are not well defined. Therefore, to begin to define and assess this, we used an isocaloric control diet (CD) and two HFDs enriched with either olive oil (OOBD, high in oleate, and unsaturated fatty acid in MDs) or a milk fat-based diet (MFBD, high in palmitate and myristate, saturated fatty acids in Western diets) in a mammary polyomavirus middle T antigen mouse model (MMTV-PyMT) of breast cancer. Our data demonstrate that neither MFBD or OOBD altered the growth of primary tumors in the MMTV-PyMT mice. The examination of lung metastases revealed that OOBD mice exhibited fewer surface nodules and smaller metastases when compared to MFBD and CD mice. These data suggest that different fatty acids found in different sources of HFDs may alter breast cancer metastasis.
Collapse
Affiliation(s)
- Fabiola N. Velazquez
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; (F.N.V.); (V.V.); (J.M.); (L.Z.); (C.T.); (Y.A.H.); (L.M.O.)
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Valentina Viscardi
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; (F.N.V.); (V.V.); (J.M.); (L.Z.); (C.T.); (Y.A.H.); (L.M.O.)
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Julia Montemage
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; (F.N.V.); (V.V.); (J.M.); (L.Z.); (C.T.); (Y.A.H.); (L.M.O.)
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Leiqing Zhang
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; (F.N.V.); (V.V.); (J.M.); (L.Z.); (C.T.); (Y.A.H.); (L.M.O.)
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Carolena Trocchia
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; (F.N.V.); (V.V.); (J.M.); (L.Z.); (C.T.); (Y.A.H.); (L.M.O.)
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Megan M. Delamont
- Department of Nutritional Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ 85721, USA;
| | - Rasheed Ahmad
- Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait;
| | - Yusuf A. Hannun
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; (F.N.V.); (V.V.); (J.M.); (L.Z.); (C.T.); (Y.A.H.); (L.M.O.)
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Lina M. Obeid
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; (F.N.V.); (V.V.); (J.M.); (L.Z.); (C.T.); (Y.A.H.); (L.M.O.)
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Ashley J. Snider
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; (F.N.V.); (V.V.); (J.M.); (L.Z.); (C.T.); (Y.A.H.); (L.M.O.)
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
- Immunology & Microbiology Department, Dasman Diabetes Institute, Kuwait City 15462, Kuwait;
- Correspondence: ; Tel.: +1-520-621-8093
| |
Collapse
|
3
|
Velazquez FN, Zhang L, Viscardi V, Trocchia C, Hannun YA, Obeid LM, Snider AJ. Loss of sphingosine kinase 1 increases lung metastases in the MMTV-PyMT mouse model of breast cancer. PLoS One 2021; 16:e0252311. [PMID: 34043703 PMCID: PMC8158862 DOI: 10.1371/journal.pone.0252311] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 05/13/2021] [Indexed: 12/11/2022] Open
Abstract
Breast cancer is a very heterogeneous disease, and ~30% of breast cancer patients succumb to metastasis, highlighting the need to understand the mechanisms of breast cancer progression in order to identify new molecular targets for treatment. Sphingosine kinase 1 (SK1) has been shown to be upregulated in patients with breast cancer, and several studies have suggested its involvement in breast cancer progression and/or metastasis, mostly based on cell studies. In this work we evaluated the role of SK1 in breast cancer development and metastasis using a transgenic breast cancer model, mouse mammary tumor virus-polyoma middle tumor-antigen (MMTV-PyMT), that closely resembles the characteristics and evolution of human breast cancer. The results show that SK1 deficiency does not alter tumor latency or growth, but significantly increases the number of metastatic lung nodules and the average metastasis size in the lung of MMTV-PyMT mice. Additionally, analysis of Kaplan-Meier plotter of human disease shows that high SK1 mRNA expression can be associated with a better prognosis for breast cancer patients. These results suggest a metastasis-suppressing function for SK1 in the MMTV-PyMT model of breast cancer, and that its role in regulating human breast cancer progression and metastasis may be dependent on the breast cancer type.
Collapse
Affiliation(s)
- Fabiola N. Velazquez
- Department of Medicine, Stony Brook University, Stony Brook, NY, United States of America
- Cancer Center, Stony Brook University, Stony Brook, NY, United States of America
| | - Leiqing Zhang
- Department of Medicine, Stony Brook University, Stony Brook, NY, United States of America
- Cancer Center, Stony Brook University, Stony Brook, NY, United States of America
| | - Valentina Viscardi
- Department of Medicine, Stony Brook University, Stony Brook, NY, United States of America
- Cancer Center, Stony Brook University, Stony Brook, NY, United States of America
| | - Carolena Trocchia
- Department of Medicine, Stony Brook University, Stony Brook, NY, United States of America
- Cancer Center, Stony Brook University, Stony Brook, NY, United States of America
| | - Yusuf A. Hannun
- Department of Medicine, Stony Brook University, Stony Brook, NY, United States of America
- Cancer Center, Stony Brook University, Stony Brook, NY, United States of America
| | - Lina M. Obeid
- Department of Medicine, Stony Brook University, Stony Brook, NY, United States of America
- Cancer Center, Stony Brook University, Stony Brook, NY, United States of America
| | - Ashley J. Snider
- Department of Medicine, Stony Brook University, Stony Brook, NY, United States of America
- Cancer Center, Stony Brook University, Stony Brook, NY, United States of America
- Department of Nutritional Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ, United States of America
- * E-mail:
| |
Collapse
|
4
|
Wagner PM, Prucca CG, Velazquez FN, Sosa Alderete LG, Caputto BL, Guido ME. Temporal regulation of tumor growth in nocturnal mammals: In vivo studies and chemotherapeutical potential. FASEB J 2021; 35:e21231. [PMID: 33428275 DOI: 10.1096/fj.202001753r] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 10/28/2020] [Accepted: 11/12/2020] [Indexed: 11/11/2022]
Abstract
Tumors of the nervous system including glioblastoma multiforme (GBM) are the most frequent and aggressive form of brain tumors; however, little is known about the impact of the circadian timing system on the formation, growth, and treatment of these tumors. We investigated day/night differences in tumor growth after injection of A530 glioma cells isolated from malignant peripheral nerve sheath tumor (MPNSTs) of NPcis (Trp53+/- ; Nf1+/- ) mice. Synchronized A530 cell cultures expressing typical glial markers were injected at the beginning of the day or night into the sciatic nerve zone of C57BL/6 mice subject to a 12:12 hours light/dark (LD) cycle or after being released to constant darkness (DD). Tumors generated in animals injected early at night in the LD cycle or in DD showed higher growth rates than in animals injected diurnally. No differences were found when animals were injected at the same time with cultures synchronized 12 hours apart. Similar experiments performed with B16 melanoma cells showed higher tumor growth rates in animals injected at the beginning of the night compared to those injected in the daytime. A higher tumor growth rate than that in controls was observed when mice were injected with knocked-down clock gene Bmal1 cells. Finally, when we compared day/night administration of different doses of the proteasome inhibitor Bortezomib (0.5-1.5 mg/kg) in tumor-bearing animals, we found that low-dose chemotherapy displayed higher efficacy when administered at night. Results suggest the existence of a precise temporal control of tumor growth and of drug efficacy in which the host state and susceptibility are critical.
Collapse
Affiliation(s)
- Paula M Wagner
- Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC)-CONICET, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba, Argentina
- Departamento de Química Biológica "Ranwel Caputto", Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - César G Prucca
- Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC)-CONICET, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba, Argentina
- Departamento de Química Biológica "Ranwel Caputto", Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Fabiola N Velazquez
- Stony Brook Cancer Center and the Department of Medicine,, Stony Brook University, Stony Brook, USA
| | - Lucas G Sosa Alderete
- Instituto de Biotecnología Ambiental y Salud (INBIAS, UNRC-CONICET). Facultad de Ciencias Exactas, Físico-Químicas y Naturales, Universidad Nacional de Río Cuarto, Río Cuarto, Córdoba, Argentina
| | - Beatriz L Caputto
- Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC)-CONICET, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba, Argentina
- Departamento de Química Biológica "Ranwel Caputto", Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Mario E Guido
- Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC)-CONICET, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba, Argentina
- Departamento de Química Biológica "Ranwel Caputto", Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| |
Collapse
|
5
|
Velazquez FN, Hernandez-Corbacho M, Trayssac M, Stith JL, Bonica J, Jean B, Pulkoski-Gross MJ, Carroll BL, Salama MF, Hannun YA, Snider AJ. Bioactive sphingolipids: Advancements and contributions from the laboratory of Dr. Lina M. Obeid. Cell Signal 2020; 79:109875. [PMID: 33290840 PMCID: PMC8244749 DOI: 10.1016/j.cellsig.2020.109875] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 02/06/2023]
Abstract
Sphingolipids and their synthetic enzymes have emerged as critical mediators in numerous diseases including inflammation, aging, and cancer. One enzyme in particular, sphingosine kinase (SK) and its product sphingosine-1-phosphate (S1P), has been extensively implicated in these processes. SK catalyzes the phosphorylation of sphingosine to S1P and exists as two isoforms, SK1 and SK2. In this review, we will discuss the contributions from the laboratory of Dr. Lina M. Obeid that have defined the roles for several bioactive sphingolipids in signaling and disease with an emphasis on her work defining SK1 in cellular fates and pathobiologies including proliferation, senescence, apoptosis, and inflammation.
Collapse
Affiliation(s)
- Fabiola N Velazquez
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Maria Hernandez-Corbacho
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Magali Trayssac
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Jeffrey L Stith
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Joseph Bonica
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11790, USA
| | - Bernandie Jean
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Michael J Pulkoski-Gross
- Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11790, USA
| | - Brittany L Carroll
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11790, USA
| | - Mohamed F Salama
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA; Department of Biochemistry, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt
| | - Yusuf A Hannun
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| | - Ashley J Snider
- Department of Nutritional Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ 85721, USA.
| |
Collapse
|
6
|
Stith JL, Velazquez FN, Obeid LM. Advances in determining signaling mechanisms of ceramide and role in disease. J Lipid Res 2019; 60:913-918. [PMID: 30846529 PMCID: PMC6495170 DOI: 10.1194/jlr.s092874] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 02/22/2019] [Indexed: 02/07/2023] Open
Abstract
Ceramide is a critical bioactive lipid involved in diverse cellular processes. It has been proposed to regulate cellular processes by influencing membrane properties and by directly interacting with effector proteins. Advances over the past decade have improved our understanding of ceramide as a bioactive lipid. Generation and characterization of ceramide-metabolizing enzyme KO mice, development of specific inhibitors and ceramide-specific antibodies, use of advanced microscopy and mass spectrometry, and design of synthetic ceramide derivatives have all provided insight into the signaling mechanisms of ceramide and its implications in disease. As a result, the role of ceramide in biological functions and disease are now better understood, with promise for development of therapeutic strategies to treat ceramide-regulated diseases.
Collapse
Affiliation(s)
- Jeffrey L Stith
- Stony Brook Cancer Center and the Department of Medicine, Health Sciences Center, Stony Brook University, Stony Brook, NY 11794
| | - Fabiola N Velazquez
- Stony Brook Cancer Center and the Department of Medicine, Health Sciences Center, Stony Brook University, Stony Brook, NY 11794
| | - Lina M Obeid
- Stony Brook Cancer Center and the Department of Medicine, Health Sciences Center, Stony Brook University, Stony Brook, NY 11794; Northport Veterans Affairs Medical Center Northport, NY 11768.
| |
Collapse
|
7
|
Velazquez FN, Miretti M, Baumgartner MT, Caputto BL, Tempesti TC, Prucca CG. Effectiveness of ZnPc and of an amine derivative to inactivate Glioblastoma cells by Photodynamic Therapy: an in vitro comparative study. Sci Rep 2019; 9:3010. [PMID: 30816179 PMCID: PMC6395748 DOI: 10.1038/s41598-019-39390-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Accepted: 01/17/2019] [Indexed: 12/31/2022] Open
Abstract
Glioblastoma multiforme is considered to be one of the most aggressive types of tumors of the central nervous system, with a poor prognosis and short survival periods of ~ one year. The current protocol for glioblastoma treatment includes the surgical excision of the primary tumor followed by radio and chemotherapy. Photodynamic therapy (PDT) is considered a promising strategy for the treatment of several types of tumors. Phthalocyanines (Pcs) are good photosensitizers (PSs) for PDT because they induce cell death in several cellular models. ZnPc (Zn(II)phthalocyanine) is a well-known Pc, extensively tested in different cells and tumor models, but its evaluation on a glioblastoma model has been poorly studied. Herein, we compare the capacity of ZnPc and one of its derivatives, Zn(II)tetraminephthalocyanine (TAZnPc), to photoinactivate glioblastoma cells (T98G, MO59, LN229 and U87-MG) in culture. We measured the cellular uptake, the toxicity in the dark and the subcellular localization of the different Pcs, as well as the clonogenic capacity of surviving cells after PDT. The mechanism of cell death induced after PDT was determined by measuring caspase 3 activation, DNA fragmentation, phosphatidylserine externalization, mitochondrial morphological changes and loss of mitochondrial membrane potential as well as lysosomal membrane integrity. Overall, ZnPc and TAZnPc present good properties to be used as PSs with photoinactivation capacity on glioblastoma cells.
Collapse
Affiliation(s)
- Fabiola N Velazquez
- CIQUIBIC (CONICET), Departamento de Química Biológica Ranwel Caputto, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Mariana Miretti
- INFIQC (CONICET), Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Maria T Baumgartner
- INFIQC (CONICET), Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Beatriz L Caputto
- CIQUIBIC (CONICET), Departamento de Química Biológica Ranwel Caputto, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Tomas C Tempesti
- INFIQC (CONICET), Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
| | - César G Prucca
- CIQUIBIC (CONICET), Departamento de Química Biológica Ranwel Caputto, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
| |
Collapse
|
8
|
Affiliation(s)
- Fabiola N Velazquez
- CIQUIBIC (CONICET), Departamento de Química Biológica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Beatriz L Caputto
- CIQUIBIC (CONICET), Departamento de Química Biológica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - François D Boussin
- Laboratoire de Radiopathologie, UMR967, Université Paris VII, Université Paris XI, INSERM, CEA, Fontenay-aux-Roses, France
| |
Collapse
|
9
|
Ferrero GO, Velazquez FN, Caputto BL. The kinase c-Src and the phosphatase TC45 coordinately regulate c-Fos tyrosine phosphorylation and c-Fos phospholipid synthesis activation capacity. Oncogene 2011; 31:3381-91. [PMID: 22105363 DOI: 10.1038/onc.2011.510] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Our previous work showed that in T98G cells, a human glioblastoma multiforme-derived cell line, the association of c-Fos to the endoplasmic reticulum (ER) and consequently, the capacity of c-Fos to activate phospholipid synthesis, is regulated by the phosphorylation state of tyrosine (tyr) residues #10 and #30 of c-Fos. The small amount of c-Fos present in quiescent cells is tyr-phosphorylated, is dissociated from the ER membranes and does not activate phospholipid synthesis. However, on induction of the cell to re-enter growth, c-Fos expression is rapidly induced, it is found dephosphorylated, associated to ER membranes and activating phospholipid synthesis (Portal et al., 2007). Herein, using in vivo and in vitro experimental strategies, we show that the kinase c-Src is capable of phosphorylating tyr residues of c-Fos whereas the phosphatase TC45 T-cell protein-tyr phosphatase (TC-PTP) dephosphorylates them, thus enabling c-Fos/ER association and activation of phospholipid synthesis. Results also suggest that the regulation of the phosphorylation/dephosphorylation cycle of c-Fos occurs at the TC-PTP level: induction of cells to re-enter growth promotes the translocation of TC45 from a nuclear to a cytoplasmic location concomitant with its activation. Activated TC45 in its turn promotes dephosphorylation of pre-formed c-Fos, enabling cells to rapidly activate phospholipid synthesis to respond to its growth demands.
Collapse
Affiliation(s)
- G O Ferrero
- CIQUIBIC (CONICET), Departamento de Química Biológica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | | | | |
Collapse
|